Search results for "Cancer development"

showing 10 items of 30 documents

Role of Natural Bioactive Compounds in the Rise and Fall of Cancers

2020

Recent years have seen the idea of a close association between nutrition and the modulation of cancer development/progression reinforced. In fact, an increasing number of experimental and epidemiological evidence have been produced supporting the concept that many different bioactive components of food (e.g. polyphenols, mono- and polyunsaturated fatty acids, methyl-group donors….) may be implicated in either the promotion of or the protection against carcinogenesis. At cellular level, such compounds can have an impact on different but sometimes intertwined processes, such as growth and differentiation, DNA repair, programmed cell death, and oxidative stress. In addition, compelling evidenc…

Cancer Researchn/acancer bioactive factorsEditorialOncologybusiness.industryCancer researchMedicineCancer developmentSettore BIO/06 - Anatomia Comparata E Citologialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensbusinesslcsh:RC254-282Cancers
researchProduct

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

2020

Abstract The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML), compared with placebo. In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase domain (TKD) mutations. At a median follow-up of 60.7 months (95% CI, 55.0-70.8), the 5-year event-free survival (EFS) rate was significantly higher in patients treated with midostaurin than in those treated with placebo (45.2% vs 30.1%; P = .044). A trend toward improved …

Oncologymedicine.medical_specialtyNPM1Myeloidmedicine.medical_treatmentCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Context (language use)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterInternal medicinehemic and lymphatic diseasesmedicineHumansMidostaurinChemotherapyMyeloid Neoplasiabusiness.industryMyeloid leukemiaHematologyStaurosporineSettore MED/15medicine.diseaseTransplantationLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structurefms-Like Tyrosine Kinase 3chemistry030220 oncology & carcinogenesisMutationbusinessNucleophosmin030215 immunology
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct

2019

Gerontologybusiness.industryMedicineGeneral MedicineSedentary behaviorCancer developmentbusinessInternational Journal of Surgery Oncology
researchProduct

Pan-cancer analysis of whole genomes

2020

Publisher's version (útgefin grein)

Maletert promoter mutationsCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]DNA Mutational AnalysisNormal tissuesystematic analysisGermlineTranscriptome0302 clinical medicineAetiologyCàncerCellular SenescenceCancer0303 health sciencesdna-damageMassive parallel sequencingPan cancerREARRANGEMENTSHigh-Throughput Nucleotide SequencingGenomicsSciences bio-médicales et agricolesTelomereCOMPREHENSIVE3. Good healthTERT PROMOTER MUTATIONSsignatures030220 oncology & carcinogenesisScience & Technology - Other TopicsErfðarannsóknirHuman:Informàtica::Aplicacions de la informàtica::Bioinformàtica [Àrees temàtiques de la UPC]EvolutionRNA SplicingGenomicsArticleEvolution MolecularStructural variationRC025403 medical and health sciencesSDG 3 - Good Health and Well-beingGeneticgenomicsSYSTEMATIC ANALYSISGeneticsGenomics--Databases.HumansGenetic TestingMolecular BiologySIGNATURESWhole genome sequencing1000 MultidisciplinaryChromothripsisScience & TechnologyRC0254 Neoplasms. Tumors. Oncology (including Cancer)Information DisseminationResearchInstitutes_Networks_Beacons/mcrcPreventionBiology and Life SciencesMolecularOncogenesCloud Computingmedicine.diseaseGenòmicaCompute cloudsMutation570 Life sciences; biologyCOMPREHENSIVE CHARACTERIZATIONGenèticaWhole Genome Sequencing--methodsBackground informationDNA Mutational Analysis ; Evolution ; Genetic / genetics ; Genome ; Genomics ; Germ-Line Mutation / genetics ; High-Throughput Nucleotide Sequencing ; Human / genetics ; Humans ; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes ConsortiumMedizinGenomeWhole-genomeGenome mappingNeoplasms2.1 Biological and endogenous factorsPromoter Regions GeneticCàncer -- Aspectes genèticsTelomeraseGeneticsWomen's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]MultidisciplinaryChromothripsisGenomeManchester Cancer Research Centregenomics cancer profiling3rd-DAS10124 Institute of Molecular Life SciencesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]Multidisciplinary SciencesParallel sequencingICGC/TCGA Pan-Cancer Analysis of Whole Genomes ConsortiumFemaleprofilingMedical GeneticsEngineering sciences. TechnologyBiotechnologyGeneral Science & TechnologyThe Cancer Genome Atlas610 Medicine & healthComputational biologyQH426 GeneticsBiologyConsortium of the International Cancer Genome ConsortiumPromoter RegionsGermline mutationPan-cancer analysisKrabbameinsrannsóknirmedicinecancerddc:610QH426Germ-Line MutationMedicinsk genetikKrabbamein030304 developmental biologyCell ProliferationLANDSCAPEGenome Humancomprehensive characterizationPan-cancer analysis of whole genomesPoint mutationHuman GenomeCancerReproducibility of ResultsSOMATIC MUTATIONSEVOLUTIONCancer sequencing Chromothripsis telomereDNA-DAMAGEMutagenesisPATTERNS3111 BiomedicineCHARACTERIZATION
researchProduct

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk C…

2017

Patients with chronic lymphocytic leukemia with del(17p) or del(11q) have poor long-term prognosis with targeted therapies. Conversely, this retrospective European Society for Blood and Marrow Transplantation registry study shows that young high cytogenetic risk responsive patients with human leukocyte antigen-matched donors have a high 8-year progression-free survival and low 2-year non-relapse mortality after allogeneic stem cell transplantation. This treatment then may compare favorably with targeted therapies for younger high cytogenetic risk patients.Background: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free sur…

MaleOncologyCancer ResearchTransplantation ConditioningBLOODCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatmentChronic lymphocytic leukemiaMedizinMULTICENTERKaplan-Meier EstimateHematopoietic stem cell transplantationTHERAPYchemistry.chemical_compound0302 clinical medicineHLA AntigensRisk FactorsIBRUTINIBeducation.field_of_studyHazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedPrognosisRELAPSED CLLTissue DonorsEUROPEAN-SOCIETY3. Good healthRisk factor analysisTreatment OutcomeOncology030220 oncology & carcinogenesisIbrutinibSURVIVALFemaleRefractory Chronic Lymphocytic LeukemiaAdultmedicine.medical_specialty3122 CancersPopulationHLA-matched donorMARROW TRANSPLANTATION03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterNon-relapse mortalityInternal medicinemedicineHumansTransplantation HomologouseducationAgedRetrospective StudiesChromosome Aberrationsbusiness.industryKinase- and BCL2 inhibitor refractorymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryTransplantationchemistryMATCHED UNRELATED DONORdel(17p)FOLLOW-UPbusiness030215 immunology
researchProduct

ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition

2019

Abstract Background Colorectal cancer (CRC) represents a relevant public health problem. The identification of new markers involved in the mechanisms of invasiveness represents a priority in order to better understand cancer development and generate new therapeutic targets. Recently, our group demonstrated overexpression of ZNF518B gene, which encodes an unknown zinc finger transcription factor, in CRC. A transcriptome-wide gene expression profile revealed its implication in different biological processes related to the progression of CRC, especially in the epithelial to mesenchymal transition (EMT). Methods To study the biological processes regulated by ZNF518B, we performed a ClariomS Arr…

HCT116 CellOncologymedicine.medical_specialtyTranscriptional factorColorectal cancerbusiness.industryeducationTranslational researchHematologymedicine.diseaseIn vitro analysisOncologyInternal medicinemedicineCancer developmentEpithelial–mesenchymal transitionbusinessSignalling pathwayshealth care economics and organizationsAnnals of Oncology
researchProduct

Ageing: from inflammation to cancer.

2018

Abstract Ageing is the major risk factor for cancer development. Hallmark of the ageing process is represented by inflammaging, which is a chronic and systemic low-grade inflammatory process. Inflammation is also a hallmark of cancer and is widely recognized to influence all cancer stages from cell transformation to metastasis. Therefore, inflammaging may represent the biological phenomena able to couple ageing process with cancer development. Here we review the molecular and cellular pathway involved in age-related chronic inflammation along with its potential triggers and their connection with cancer development.

0301 basic medicineSenescencelcsh:Immunologic diseases. AllergyAgingCellImmunologyAgeing; Cancer; DAMPs; Inflammation; MiRna; Microbiota; Obesity; SenescenceInflammationReviewlcsh:GeriatricsSenescenceMetastasis03 medical and health sciencesmicroRNAMedicineDAMPObesityCancerSettore MED/04 - Patologia GeneraleInflammationDAMPsbusiness.industryAgeing; Cancer; DAMPs; Inflammation; Microbiota; MiRna; Obesity; Senescence; Immunology; AgingMicrobiotaCancermedicine.diseaselcsh:RC952-954.6Ageing030104 developmental biologymedicine.anatomical_structureAgeingCancer researchSettore MED/26 - NeurologiaCancer developmentmedicine.symptombusinesslcsh:RC581-607MiRna
researchProduct

Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting

2013

Abstract: The modern approach for metastatic colorectal cancer (mCRC) patients is based on the identification of oncogenic pathways, which could be targeted by specific molecules. Vascular endothelial growth factor (VEGF)- and epithelial growth factor receptor (EGFR)-related pathways represent the most important biological mechanisms for cancer development and progression. However, the most significant results by VEGF and EGFR targeting could be achieved through the combination of these drugs with standard chemotherapeutic regimens. These strategies aim to improve the resectability of liver and lung metastases. For those patients who cannot be eligible for metastases resection, a 'continuum…

OncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyColorectal cancerSettore MED/06 - Oncologia MedicaVEGF receptorsClinical BiochemistryResectionchemistry.chemical_compoundGrowth factor receptorInternal medicineDrug DiscoveryMedicineHumansTarget therapyContinuum of carePharmacologybiologybusiness.industryPharmacology. Therapycolon cancer EGFR target therapies VEGFmedicine.diseaseVascular endothelial growth factorErbB Receptorschemistrybiology.proteinMolecular MedicineCancer developmentbusinessColorectal Neoplasms
researchProduct

Effects of Dietary Restriction on Cancer Development and Progression

2017

The effects of caloric restriction on tumor growth and progression are known for over a century. Indeed, fasting has been practiced for millennia, but just recently has emerged the protective role that it may exert toward cells. Fasting cycles are able to reprogram the cellular metabolism, by inducing protection against oxidative stress and prolonging cellular longevity. The reduction of calorie intake as well as short- or long-term fasting has been shown to protect against chronic and degenerative diseases, such as diabetes, cardiovascular pathologies, and cancer. In vitro and in vivo preclinical models showed that different restriction dietary regimens may be effective against cancer onse…

Starvationbusiness.industryCancer evolutionDietary restriction nutrition cancer cancer progression cancer evolution starvationCancer researchMedicineCancerCancer developmentmedicine.symptombusinessmedicine.disease
researchProduct